Staying Ahead of Regulatory Change: CMC Strategies for Cell and Gene Therapy Development
The regulatory landscape for cell and gene therapies (CGTs) is shifting fast. From increased...
The regulatory landscape for cell and gene therapies (CGTs) is shifting fast. From increased...
The decision to partner with a Clinical Research Organization (CRO) is never taken...
The development of innovative oncology therapies has evolved dramatically, moving beyond...
Learn how Veristat’s multidisciplinary team helped sponsors navigate the complexities of global...
In partnership with Clinical Leader, Veristat consulting, regulatory, and clinical experts gave a...
Are you interested in learning about the latest FDA initiative to accelerate the development of new...
Learn how Veristat's expert medical writing team supported a global specialty pharmaceutical...
At Veristat, we pride ourselves on transforming challenges into triumphs, particularly in the...
In 2022, the FDA’s Center for Drug Evaluation and Research (CDER) launched the Accelerating Rare...
In the intricate world of pharmaceuticals and biotechnology, every step of drug development is...